Cancer Drugs Fund requires further reform
Reliance on “real world” observational data undermines evidence base for clinical practice.
Main Authors: | Grieve, R, Abrams, K, Claxton, K, Goldacre, B, James, N, Nicholl, J, Parmar, M, Parker, C, Sekhon, J, Smeeth, L, Spiegelhalter, D, Sculpher, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BMJ Publishing Group
2016
|
Similar Items
-
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
by: Morrell, L, et al.
Published: (2018) -
Huang Shu Yin funded for further study
by: Kwong Wah, Yit Poh
Published: (2017) -
Huang Shu Yin Funded For Further Study
by: Kwong Wah, Yit Poh
Published: (2017) -
MRE in NAFLD: promising but further validation is required
by: Ryan, J, et al.
Published: (2018) -
Results-based funding for safe drinking water services
by: Charles, K, et al.
Published: (2023)